Aetiology of hospital-acquired pneumonia and trends in antimicrobial resistance

Current Opinion in Pulmonary Medicine

Volumn 20, Issue 3, 2014, Pages 252-258

  Enne, Virve I ^a   Personne, Yoann ^a   Grgic, Ljuban ^a   Gant, Vanya ^b   Zumla, Alimuddin ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

aetiology; antibiotic resistance; hospital acquired; pneumonia; ventilator associated

Indexed keywords

ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; BACTERIAL VIRULENCE; ENCAPSULATION; GEOGRAPHICAL VARIATION (SPECIES); HOSPITAL ACQUIRED PNEUMONIA; HUMAN; OUTCOME ASSESSMENT; POINT OF CARE TESTING; REVIEW; TREND STUDY; VENTILATOR ASSOCIATED PNEUMONIA; CROSS INFECTION; DRUG EFFECTS; FEMALE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; INFECTION CONTROL; ISOLATION AND PURIFICATION; MALE; MECHANICAL VENTILATOR; MICROBIOLOGY; PNEUMONIA; PNEUMONIA, VENTILATOR-ASSOCIATED; PREVALENCE; PROCEDURES; RISK FACTOR; STANDARDS;

ANTI-BACTERIAL AGENTS; CROSS INFECTION; DRUG RESISTANCE, MICROBIAL; FEMALE; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; INFECTION CONTROL; MALE; PNEUMONIA; PNEUMONIA, VENTILATOR-ASSOCIATED; PREVALENCE; RISK FACTORS; VENTILATORS, MECHANICAL;

EID: 84897581465     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0000000000000042     Document Type: Review

References (59)

1. American Thoracic Society Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171:388-416.
2. Giard M, Lepape A, Allaouchiche B, et al. Early-and late-onset ventilatorassociated pneumonia acquired in the intensive care unit: comparison of risk factors. J Crit Care 2008; 23:27-33.
3. Bassetti M, Taramasso L, Giacobbe DR, Pelosi P. Management of ventilatorassociated pneumonia: epidemiology, diagnosis and antimicrobial therapy. Expert Rev Anti Infect Ther 2012; 10:585-596.
4. Restrepo MI, Peterson J, Fernandez JF, et al. Comparison of the bacterial etiology of early-onset and late-onset ventilator-associated pneumonia in subjects enrolled in 2 large clinical studies. Respir Care 2013; 58:1220-1225.
5. Caceres F, Welch VL, Kett DH, et al., The Impact-Hap Study Group. Absence of gender-based differences in outcome of patients with hospital-acquired pneumonia. J Womens Health (Larchmt) 2013; 22:1069-1075.
6. Patria MF, Chidini G, Ughi L, et al. Ventilator-associated pneumonia in an Italian pediatric intensive care unit: a prospective study. World J Pediatr 2013; 9:365-368.
7. Srinivasan R, Asselin J, Gildengorin G, et al. A prospective study of ventilatorassociated pneumonia in children. Pediatrics 2009; 123:1108-1115.
8. Finegold SM. Aspiration pneumonia. Rev Infect Dis 1991; 13:S737-S742.
9. Iwata K, Igarashi W, Honjo M, et al. Hospital-acquired pneumonia in Japan may have a better mortality profile than HAP in the United States: a retrospective study. J Infect Chemother 2012; 18:734-740.
10. Seligman R, Ramos-Lima LF, Oliveira VD, et al. Risk factors for infection with multidrug-resistant bacteria in nonventilated patients with hospital-acquired pneumonia. J Bras Pneumol 2013; 39:339-348.
11. Chung DR, Song JH, Kim SH, et al. High prevalence of multidrug-resistant nonfermenters in hospital-acquired pneumonia in Asia. Am J Resp Crit Care Med 2011; 184:1409-1417.
12. Reechaipichitkul W, Phondongnok S, Bourpoern J, Chaimanee P. Causative agents and resistance among hospital-acquired and ventilator-associated pneumonia patients at Srinagarind hospital, northeastern Thailand. Southeast Asian J Trop Med Public Health 2013; 44:490-502.
13. Kunac A, Sifri ZC, Mohr AM, et al. Bacteremia and ventilator-associated pneumonia: a marker for contemporaneous extra-pulmonic infection. Surg Infect (Larchmt) 2013. [Epub ahead of print]
14. Sandiumenge A, Lisboa T, Gomez F, et al. Effect of antibiotic diversity on ventilator-associated pneumonia caused by ESKAPE organisms. Chest 2011; 140:643-651.
15. El-Saed A, Balkhy HH, Al-Dorzi HM, et al. Acinetobacter is the most common pathogen associated with late-onset and recurrent ventilator-associated pneumonia in an adult intensive care unit in Saudi Arabia. Int J Infect Dis 2013; 17:E696-E701.
16. Sandiumenge A, Rello J. Ventilator-associated pneumonia caused by ESKAPE organisms: cause, clinical features, and management. Curr Opin Pulm Med 2012; 18:187-193.
17. Jones RN. Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Clin Infect Dis 2010; 51 (Suppl 1): S81-S87.
18. Lopez-Giraldo A, Sialer S, Esperatti M, Torres A. Viral-reactivated pneumonia during mechanical ventilation: is there need for antiviral treatment? Front Pharmacol 2011; 2:66.
19. Costa C, Bergallo M, Astegiano S, et al. Detection of Mimivirus in bronchoalveolar lavage of ventilated and nonventilated patients. Intervirology 2012; 55:303-305.
20. Vincent A, La Scola B, Forel JM, et al. Clinical significance of a positive serology for mimivirus in patients presenting a suspicion of ventilator-associated pneumonia. Crit Care Med 2009; 37:111-118.
21. Dare RK, Chittaganpitch M, Erdman DD. Screening pneumonia patients for mimivirus. Emerg Infect Dis 2008; 14:465-467.
22. Hamet M, Pavon A, Dalle F, et al. Candida spp. airway colonization could promote antibiotic-resistant bacteria selection in patients with suspected ventilator-associated pneumonia. Intensive Care Med 2012; 38:1272-1279.
23. Meersseman W, Lagrou K, Spriet I, et al. Significance of the isolation of Candida species from airway samples in critically ill patients: a prospective, autopsy study. Intensive Care Med 2009; 35:1526-1531.
24. Blot SI, Taccone FS, Van den Abeele AM, et al. A clinical algorithm to diagnose invasive pulmonary aspergillosis in critically ill patients. Am J Respir Crit Care Med 2012; 186:56-64.
25. Ferrer M, Liapikou A, Valencia M, et al. Validation of the American Thoracic Society-Infectious Diseases Society of America guidelines for hospitalacquired pneumonia in the intensive care unit. Clin Infect Dis 2010; 50:945-952.
26. Flanagan JL, Brodie EL, Weng L, et al. Loss of bacterial diversity during antibiotic treatment of intubated patients colonized with Pseudomonas aeruginosa. J Clin Microbiol 2007; 45:1954-1962.
27. Rosenthal VD, Hu BJ, Maki DG, et al. International Nosocomial Infection Control Consortium (INICC) report, data summary of 36 countries, for 2004-2009. Am J Infect Cont 2012; 40:396-407.
28. Hoban DJ, Biedenbach DJ, Mutnick AH, Jones RN. Pathogen of occurrence and susceptibility patterns associated with pneumonia in hospitalized patients in North America: results of the SENTRY Antimicrobial Surveillance Study (2000). Diagn Microb Infect Dis 2003; 45:279-285.
29. Gales AC, Sader HS, Jones RN. Respiratory tract pathogens isolated from patients hospitalized with suspected pneumonia in Latin America: frequency of occurrence and antimicrobial susceptibility profile: results from the SENTRY Antimicrobial Surveillance Program (1997-2000). Diagn Microb Infect Dis 2002; 44:301-311.
30. Canton R, Coque TM, Baquero F. Multiresistant Gram-negative bacilli: from epidemics to endemics. Curr Opin Infect Dis 2003; 16:315-325.
31. Canton R, Akova M, Carmeli Y, et al. Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe. Clin Microbiol Infect 2012; 18:413-431.
32. Walsh TR. Emerging carbapenemases: a global perspective. Int J Antimicrob Agents 2010; 36:S8-S14.
33. Carattoli A. Plasmids in Gram negatives: molecular typing of resistance plasmids. Int J Med Microbiol 2011 1012; 301:654-658.
34. Vicari G, Bauer SR, Neuner EA, Lam SW. Association between colistin dose and microbiologic outcomes in patients with multidrug-resistant Gram-negative bacteremia. Clin Infect Dis 2013; 56:398-404.
35. Zavascki AP, Bulitta JB, Landersdorfer CB. Combination therapy for carbapenem-resistant Gram-negative bacteria. Expert Rev Anti-Infect Ther 2013; 11:1333-1353.
36. Rolain J-M, Diene SM, Kempf M, et al. Real-time sequencing to decipher the molecular mechanism of resistance of a clinical pan-drug-resistant Acinetobacter baumannii isolate from Marseille, France. Antimicrob Agents Chemother 2013; 57:592-596.
37. Sader HS, Flamm RK, Jones RN. Tigecycline activity tested against antimicrobial resistant surveillance subsets of clinical bacteria collected worldwide (2011). Diagn Microb Infect Dis 2013; 76:217-221.
38. Peleg AY, Adams J, Paterson DL. Tigecycline efflux as a mechanism for nonsusceptibility in Acinetobacter baumannii. Antimicrob Agents Chemother 2007; 51:2065-2069.
39. Cai Y, Chai D, Wang R, et al. Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies. J Antimicrob Chemother 2012; 67:1607-1615.
40. McPhee JB, Lewenza S, Hancock REW. Cationic antimicrobial peptides activate a two-component regulatory system, PmrA-PmrB, that regulates resistance to polymyxin B and cationic antimicrobial peptides in Pseudomonas aeruginosa. Mol Microbiol 2003; 50:205-217.
41. Morales G, Picazo JJ, Baos E, et al. Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolid-resistant Staphylococcus aureus. Clin Infect Dis 2010; 50:821-825.
42. Gu B, Kelesidis T, Tsiodras S, et al. The emerging problem of linezolidresistant Staphylococcus. J Antimicrob Chemother 2013; 68:4-11.
43. Krause KM, Blais J, Lewis SR, et al. In vitro activity of telavancin and occurrence of vancomycin heteroresistance in isolates from patients enrolled in phase 3 clinical trials of hospital-acquired pneumonia. Diagn Microb Infect Dis 2012; 74:429-431.
44. Bousbia S, Raoult D, La Scola B. Pneumonia pathogen detection and microbial interactions in polymicrobial episodes. Future Microbiol 2013; 8:633-660.
45. Murray PR. What is new in clinical microbiology microbial identification by MALDI-TOF mass spectrometry: a paper from the 2011 William Beaumont Hospital symposium on molecular pathology. J Mol Diagn 2012; 14:419-423.
46. Seng P, Abat C, Rolain JM, et al. Identification of rare pathogenic bacteria in a clinical microbiology laboratory: impact of matrix-assisted laser desorption ionization-time of flight mass spectrometry. J Clin Microbiol 2013; 51:2182-2194.
47. Seng P, Drancourt M, Gouriet F, et al. Ongoing revolution in bacteriology: routine identification of bacteria by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. Clin Infect Dis 2009; 49:543-551.
48. Lung ML, Codina G. Molecular diagnosis in HAP/VAP. Curr Opin Crit Care 2012; 18:487-494.
49. RiD-RTI. RiD-RTI rapid identification of respiratory tract infections. http://www.rid-rti.eu. [Accessed 10 January 2014]
50. Curetis. Curetis UNYVERO pneumonia application guide, product insert. http://www.curetis.com/fileadmin/curetis/media/struktur/Products/Instructions/ 00118-Unyvero-Pneumonia-Application-Guide-V2-0.pdf>2012. [Accessed 10 January 2014]
51. Bogaerts P, Hamels S, de Mendonca R, et al. Analytical validation of a novel high multiplexing real-time PCR array for the identification of key pathogens causative of bacterial ventilator-associated pneumonia and their associated resistance genes. J Antimicrob Chemother 2013; 68:340-347.
52. Cercenado E, Marin M, Burillo A, et al. Rapid detection of Staphylococcus aureus in lower respiratory tract secretions from patients with suspected ventilator-associated pneumonia: evaluation of the Cepheid Xpert MRSA/SA SSTI Assay. J Clin Microbiol 2012; 50:4095-4097.
53. Bousbia S, Papazian L, Saux P, et al. Repertoire of intensive care unit pneumonia microbiota. PLos One 2012; 7:e32486.
54. Endimiani A, Hujer KM, Hujer AM, et al. Are we ready for novel detection methods to treat respiratory pathogens in hospital-acquired pneumonia? Clin Infect Dis 2011; 52:S373-S383.
55. Tenover FC. Developing molecular amplification methods for rapid diagnosis of respiratory tract infections caused by bacterial pathogens. Clin Infect Dis 2011; 52:S338-S345.
56. Chastre J. Ventilator-associated pneumonia: what is new? Surg Infect (Larchmt) 2006; 7:S81-S85.
57. The National Archives. High impact intervention care bundle to reduce ventilation-association pneumonia. http://webarchive.nationalarchives.gov. uk/20120118164404/hcai.dh.gov.uk/files/2011/03/2011-03-14-HII-Ventila tor-Associated-Pneumonia-FINAL.pdf. [Accessed 10 January 2014]
58. Chaari A, Zribi E, Dammak H, et al. Does selective digestive decontamination prevent ventilator-associated pneumonia in trauma patients? Am J Ther 2013; 5:5.
59. Camus C, Salomon S, Bouchigny C, et al. Short-term decline in all-cause acquired infections with the routine use of a decontamination regimen combining topical polymyxin, tobramycin, and amphotericin B with mupirocin and chlorhexidine in the ICU: a single-center experience. Crit CareMed 2013; 20:20.